Sarepta Therapeutics Inc (SRPT)

Fixed asset turnover

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Revenue (ttm)	US$ in thousands	1,403,300	1,243,336	1,104,982	1,003,434	975,683	933,013	876,047	835,184	765,786	701,887	645,564	600,082	573,356	540,099	495,074	450,191	407,496	380,833	365,135	344,580
Property, plant and equipment	US$ in thousands	249,302	227,154	212,367	188,874	182,862	180,037	181,005	183,292	187,248	191,156	199,249	203,330	203,107	190,430	171,715	153,340	137,325	129,620	119,532	117,201
Fixed asset turnover		5.63	5.47	5.20	5.31	5.34	5.18	4.84	4.56	4.09	3.67	3.24	2.95	2.82	2.84	2.88	2.94	2.97	2.94	3.05	2.94

March 31, 2024 calculation

Fixed asset turnover = Revenue (ttm) ÷ Property, plant and equipment
= $1,403,300K ÷ $249,302K
= 5.63

Sarepta Therapeutics Inc's fixed asset turnover ratio has been fluctuating over the past few quarters. The stable trend in the recent quarters suggests that the company is effectively utilizing its fixed assets to generate revenue. The ratios ranging from 5.20 to 5.63 indicate that for every dollar invested in fixed assets, the company generated between $5.20 to $5.63 in revenue.

The increasing trend from 4.09 in March 2022 to 5.63 in March 2024 signifies an improvement in efficiency in utilizing fixed assets to generate sales. This may indicate enhanced production capacity or operational efficiency. However, the ratio dip in the previous quarters may suggest temporary inefficiencies or significant changes in fixed asset utilization.

Overall, Sarepta Therapeutics Inc's fixed asset turnover shows a positive trend in recent quarters, indicating the company's ability to generate more revenue from its fixed assets. Investors and stakeholders may view this efficiency positively as it reflects effective management of the company's assets to drive revenue growth.